Overview and Pathophysiology

Onychomycosis, or tinea unguium, is a chronic fungal infection of the nail unit characterized by significant morbidity, including pain, secondary bacterial infection, and psychosocial distress. While often considered cosmetic, it can serve as a reservoir for dermatophyte transmission (e.g., Tinea pedis) and may exacerbate underlying systemic conditions.

The etiology is primarily dermatophytic, with Trichophyton rubrum being the most common pathogen globally (responsible for ~70–90% of cases). Non-dermatophytic yeasts, particularly Candida species, are more prevalent in fingernail infections and in patients with chronic moisture exposure.

Clinical Phenotypes

Accurate classification is critical as it informs both the diagnostic approach and the likely pathogen:

1. Distal Subungual Onychomycosis (DSU): The most common presentation. Characterized by subungual hyperkeratosis, onycholysis, and discoloration (yellow/brown). It typically begins at the distal free edge and progresses proximally.
2. White Superficial Onychomycosis (WSO): Characterized by focal white patches on the nail surface with crumbling texture. This form involves superficial invasion of the nail plate and is often seen in patients with frequent water exposure or hyperkeratotic nail plates.
3. Proximal Subungual Onychomycosis (PSU): Fungal invasion occurs via the proximal nail fold. This pattern is highly suggestive of either immunocompromised status (e.g., HIV, transplant recipients) or a history of traumatic nail injury.
4. Candidal Onychomycosis: Often involves the proximal nail fold (paronychia) and is more common in fingernails. It is frequently associated with chronic moisture exposure or repetitive microtrauma.

Risk Factors and Differential Diagnosis

Clinical Red Flags for Onychomycosis

Clinicians should maintain a high index of suspicion in patients presenting with:

• Tinea Pedis: Recurrent interdigital scaling (moccasin-type) is a strong predictor of subclinical onychomycosis.
• Co-morbidities: Diabetes mellitus, peripheral vascular disease (PVD), and obesity increase the risk of both infection and impaired wound healing.
• Anatomical Predispositions: Involvement of the 1st and 5th digits or unilateral involvement in a patient with systemic symptoms may suggest underlying systemic issues.

Essential Differential Diagnosis

Misdiagnosis leads to unnecessary long-term antifungal use. Key differentials include:

• Nail Psoriasis: Often presents with “oil spots” (salmon patches), pitting, and onycholysis. It may present with concomitant lichen planus or psoriatic plaques on the scalp/body.
• Lichen Planus (Nail Lichen Planus): Characterized by thinning of the nail plate, pterygium formation (scarring of the proximal nail fold), and longitudinal ridging.
• Onycholysis due to Trauma or Chemicals: Often lacks the subungual hyperkeratosis seen in fungal infections.
• Subungual Hematoma: Presents with dark discoloration but typically follows a history of trauma.

Diagnostic Gold Standards

Clinical examination alone has low specificity. Definitive diagnosis via mycological confirmation is mandatory before initiating systemic therapy.

1. KOH Wet Mount: The first-line rapid test. It identifies fungal elements (hyphae, spores) within nail clippings or subungual debris. Note: Sensitivity is limited by the high rate of false negatives if sampling is inadequate.
2. Fungal Culture: Gold standard for identifying specific species. Clinical Pearl: To increase yield, clinicians should sample from the most proximal part of the infected area (subungual detritus) rather than just the distal edge, as the distal portion often contains only debris and no viable fungus.
3. Molecular Diagnostics (PCR): Highly sensitive and specific. PCR is increasingly preferred for its ability to detect DNA even when fungal load is low or when traditional cultures are negative due to prior antifungal use. It also allows for rapid species identification.
4. Histopathology (PAS Stain): Periodic Acid-Schiff (PAS) staining of nail clippings provides definitive evidence of fungal invasion into the nail plate keratin.

Evidence-Based Management Strategies

1. Topical Therapy

Indicated for mild infections (involving <50% of a single nail, no proximal involvement) or as adjunctive therapy to oral agents.

• Ciclopirox 8% Nail Lacquer: Applied twice daily for 6–12 months. It acts via chelation of polyvalent cations required for fungal enzyme function.
• Amorolfine 5% Nail Lacquer: Applied once or twice weekly.
• Note: Topical monotherapy has high failure rates in toenail infections due to poor nail plate penetration.

2. Systemic Therapy (First-Line for Moderate-to-Severe Infection)

Systemic therapy is indicated when the nail matrix/proximal nail bed is involved or when multiple nails are affected.

• Terbinafine (Oral): The preferred first-line agent for dermatophyte infections.
  • Dosing: 250 mg orally once daily.
  • Duration: 6 weeks for fingernails; 12 weeks for toenails.
  • Monitoring: Baseline liver function tests (LFTs) are recommended, though routine monitoring is debated unless symptoms of hepatotoxicity arise.
• Itraconazole (Oral): An alternative, especially if Candida or non-dermatophyte yeasts are suspected.
  • Dosing: Pulse therapy (400 mg daily for 1 week per month for 3–6 months) is common.
  • Monitoring: Requires monitoring for drug-drug interactions (CYP450 inhibitors/inducers) and potential hepatotoxicity.

3. Surgical and Adjunctive Options

• Chemical/Surgical Avulsion: Reserved for severe, painful, or non-responsive cases where the nail plate is destroyed. Chemical debridement using urea paste can be an effective, less invasive alternative to surgical excision.

Clinical Decision Making: The “Treat vs. Observe” Paradigm

Before prescribing, clinicians must weigh the benefits against the risks:

• The “Asymptomatic” Rule: If the infection is asymptomatic and involves only a small portion of the nail, observation may be appropriate to avoid unnecessary drug exposure.
• Risk Assessment: Avoid systemic antifungals in patients with significant hepatic impairment or those on multiple medications that interact via the CYP450 pathway.
• Patient Compliance: Emphasize that nail regrowth is slow; clinical improvement (new nail growth) may take 3–6 months to become visible.